scispace - formally typeset
D

Dirk Posthouwer

Researcher at Maastricht University Medical Centre

Publications -  48
Citations -  823

Dirk Posthouwer is an academic researcher from Maastricht University Medical Centre. The author has contributed to research in topics: Hepatitis C & Hepatitis C virus. The author has an hindex of 14, co-authored 44 publications receiving 680 citations. Previous affiliations of Dirk Posthouwer include Gelre Hospitals & Utrecht University.

Papers
More filters
Journal Article

Gentamicin is frequently underdosed in patients with sepsis in the emergency department.

TL;DR: There was no difference in severity of sepsis according to the SIRS criteria in both groups, and patient characteristics comparing underdosed patients with adequately dosed patients were similar.
Journal ArticleDOI

Mpox vaccination willingness, determinants, and communication needs in gay, bisexual, and other men who have sex with men, in the context of limited vaccine availability in the Netherlands (Dutch Mpox-survey)

TL;DR: In this article , the authors study vaccine acceptance and its determinants, to target and tailor public health (communication-) strategies in the context of limited vaccine supply in the Netherlands, and assess determinants for being (un)willing to accept vaccination, including perception of higher risk/severity of monkeypox, higher protection motivation, positive outcome expectations post vaccination, and perceived positive social norms regarding vaccination.
Journal ArticleDOI

Beneficial effect of successful HCV treatment in patients with inherited bleeding disorders, assessed by liver stiffness measurements

TL;DR: Even after a long HCV infection duration, successful antiviral treatment led to a significant improvement of fibrosis, measured by LSM, mainly in the first few years after completing treatment.
Journal ArticleDOI

Treatment of chronic hepatitis C with direct acting antiviral agents in patients with haemophilia, end-stage liver disease and coinfected with HIV

TL;DR: There is a highly effective and well tolerated IFN-free regime available especially for patients with ESLD, described in this case report, of a 24 week treatment with sofosbuvir and daclatasvir in two PWH coinfected with HIV and HCV, ineligible for IFN.